These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 36763263)
21. Alterations of multiple peripheral inflammatory cytokine levels after repeated ketamine infusions in major depressive disorder. Zhan Y; Zhou Y; Zheng W; Liu W; Wang C; Lan X; Deng X; Xu Y; Zhang B; Ning Y Transl Psychiatry; 2020 Jul; 10(1):246. PubMed ID: 32699226 [TBL] [Abstract][Full Text] [Related]
22. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Murrough JW; Perez AM; Pillemer S; Stern J; Parides MK; aan het Rot M; Collins KA; Mathew SJ; Charney DS; Iosifescu DV Biol Psychiatry; 2013 Aug; 74(4):250-6. PubMed ID: 22840761 [TBL] [Abstract][Full Text] [Related]
23. Inflammatory markers and treatment outcome in treatment resistant depression: A systematic review. Yang C; Wardenaar KJ; Bosker FJ; Li J; Schoevers RA J Affect Disord; 2019 Oct; 257():640-649. PubMed ID: 31357161 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121 [TBL] [Abstract][Full Text] [Related]
25. Antidepressant and antisuicidal effects of ketamine on the functional connectivity of prefrontal cortex-related circuits in treatment-resistant depression: A double-blind, placebo-controlled, randomized, longitudinal resting fMRI study. Chen MH; Lin WC; Tu PC; Li CT; Bai YM; Tsai SJ; Su TP J Affect Disord; 2019 Dec; 259():15-20. PubMed ID: 31437695 [TBL] [Abstract][Full Text] [Related]
26. Effects of treatment refractoriness and brain-derived neurotrophic factor Val66Met polymorphism on antidepressant response to low-dose ketamine infusion. Chen MH; Lin WC; Tsai SJ; Li CT; Cheng CM; Wu HJ; Bai YM; Hong CJ; Tu PC; Su TP Eur Arch Psychiatry Clin Neurosci; 2021 Oct; 271(7):1267-1274. PubMed ID: 33959800 [TBL] [Abstract][Full Text] [Related]
27. Whole blood transcriptional signatures associated with rapid antidepressant response to ketamine in patients with treatment resistant depression. Cathomas F; Bevilacqua L; Ramakrishnan A; Kronman H; Costi S; Schneider M; Chan KL; Li L; Nestler EJ; Shen L; Charney DS; Russo SJ; Murrough JW Transl Psychiatry; 2022 Jan; 12(1):12. PubMed ID: 35013133 [TBL] [Abstract][Full Text] [Related]
28. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095 [TBL] [Abstract][Full Text] [Related]
29. Peripheral proinflammatory markers associated with ketamine response in a preclinical model of antidepressant-resistance. Walker AJ; Foley BM; Sutor SL; McGillivray JA; Frye MA; Tye SJ Behav Brain Res; 2015 Oct; 293():198-202. PubMed ID: 26209292 [TBL] [Abstract][Full Text] [Related]
30. Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression. Su TP; Chen MH; Li CT; Lin WC; Hong CJ; Gueorguieva R; Tu PC; Bai YM; Cheng CM; Krystal JH Neuropsychopharmacology; 2017 Dec; 42(13):2482-2492. PubMed ID: 28492279 [TBL] [Abstract][Full Text] [Related]
31. Role of Neuronal VEGF Signaling in the Prefrontal Cortex in the Rapid Antidepressant Effects of Ketamine. Deyama S; Bang E; Wohleb ES; Li XY; Kato T; Gerhard DM; Dutheil S; Dwyer JM; Taylor SR; Picciotto MR; Duman RS Am J Psychiatry; 2019 May; 176(5):388-400. PubMed ID: 30606046 [TBL] [Abstract][Full Text] [Related]
32. Antisuicidal effect, BDNF Val66Met polymorphism, and low-dose ketamine infusion: Reanalysis of adjunctive ketamine study of Taiwanese patients with treatment-resistant depression (AKSTP-TRD). Chen MH; Lin WC; Wu HJ; Cheng CM; Li CT; Hong CJ; Tu PC; Bai YM; Tsai SJ; Su TP J Affect Disord; 2019 May; 251():162-169. PubMed ID: 30925267 [TBL] [Abstract][Full Text] [Related]
33. Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Carlson PJ; Diazgranados N; Nugent AC; Ibrahim L; Luckenbaugh DA; Brutsche N; Herscovitch P; Manji HK; Zarate CA; Drevets WC Biol Psychiatry; 2013 Jun; 73(12):1213-21. PubMed ID: 23540908 [TBL] [Abstract][Full Text] [Related]
34. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder. Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512 [TBL] [Abstract][Full Text] [Related]
35. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial. Ionescu DF; Bentley KH; Eikermann M; Taylor N; Akeju O; Swee MB; Pavone KJ; Petrie SR; Dording C; Mischoulon D; Alpert JE; Brown EN; Baer L; Nock MK; Fava M; Cusin C J Affect Disord; 2019 Jan; 243():516-524. PubMed ID: 30286416 [TBL] [Abstract][Full Text] [Related]
36. Role of klotho on antidepressant and antisuicidal effects of low-dose ketamine infusion among patients with treatment-resistant depression and suicidal ideation. Chen MH; Bai YM; Wu HJ; Li CT; Lin WC; Tsai SJ; Su TP; Tu PC J Affect Disord; 2023 Nov; 340():471-475. PubMed ID: 37579883 [TBL] [Abstract][Full Text] [Related]
37. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Green CE; Perez AM; Iqbal S; Pillemer S; Foulkes A; Shah A; Charney DS; Mathew SJ Am J Psychiatry; 2013 Oct; 170(10):1134-42. PubMed ID: 23982301 [TBL] [Abstract][Full Text] [Related]
38. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038 [TBL] [Abstract][Full Text] [Related]
39. Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence. Lipsitz O; McIntyre RS; Rodrigues NB; Kaster TS; Cha DS; Brietzke E; Gill H; Nasri F; Lin K; Subramaniapillai M; Kratiuk K; Teopiz K; Lui LMW; Lee Y; Ho R; Shekotikhina M; Mansur RB; Rosenblat JD Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 105():110126. PubMed ID: 33031861 [TBL] [Abstract][Full Text] [Related]
40. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]